Teva Pharmaceutical Industries Limited (TEVA) Stock Rating Reaffirmed by UBS AG

Teva Pharmaceutical Industries Limited (NYSE:TEVA)‘s stock had its “neutral” rating reaffirmed by equities research analysts at UBS AG in a report released on Thursday. They currently have a $19.00 price target on the stock. UBS AG’s target price points to a potential upside of 4.97% from the stock’s current price.

TEVA has been the topic of several other research reports. Gabelli restated a “buy” rating on shares of Teva Pharmaceutical Industries Limited in a research report on Wednesday. BidaskClub upgraded shares of Teva Pharmaceutical Industries Limited from a “strong sell” rating to a “sell” rating in a research report on Wednesday. Oppenheimer Holdings, Inc. restated a “hold” rating on shares of Teva Pharmaceutical Industries Limited in a research report on Monday, September 11th. Jefferies Group LLC decreased their price target on shares of Teva Pharmaceutical Industries Limited from $21.00 to $18.50 and set a “hold” rating on the stock in a research report on Tuesday. Finally, Cantor Fitzgerald set a $17.00 price target on shares of Teva Pharmaceutical Industries Limited and gave the stock a “hold” rating in a research report on Monday, September 11th. Five investment analysts have rated the stock with a sell rating, nineteen have issued a hold rating, seven have given a buy rating and one has issued a strong buy rating to the stock. The company presently has an average rating of “Hold” and an average target price of $31.42.

Shares of Teva Pharmaceutical Industries Limited (NYSE:TEVA) opened at 18.10 on Thursday. The firm’s 50-day moving average price is $19.00 and its 200-day moving average price is $28.55. The firm’s market cap is $18.39 billion. Teva Pharmaceutical Industries Limited has a one year low of $15.22 and a one year high of $51.61.

Teva Pharmaceutical Industries Limited (NYSE:TEVA) last announced its earnings results on Thursday, August 3rd. The company reported $0.99 EPS for the quarter, missing the Thomson Reuters’ consensus estimate of $1.06 by ($0.07). Teva Pharmaceutical Industries Limited had a positive return on equity of 15.96% and a negative net margin of 25.18%. The firm had revenue of $5.69 billion for the quarter, compared to the consensus estimate of $5.72 billion. During the same period in the previous year, the firm earned $1.25 EPS. Teva Pharmaceutical Industries Limited’s revenue for the quarter was up 12.9% on a year-over-year basis. Equities research analysts expect that Teva Pharmaceutical Industries Limited will post $4.32 earnings per share for the current fiscal year.

ILLEGAL ACTIVITY NOTICE: “Teva Pharmaceutical Industries Limited (TEVA) Stock Rating Reaffirmed by UBS AG” was published by Chaffey Breeze and is the sole property of of Chaffey Breeze. If you are accessing this piece on another publication, it was stolen and republished in violation of international copyright and trademark legislation. The correct version of this piece can be accessed at https://www.chaffeybreeze.com/2017/09/16/teva-pharmaceutical-industries-limited-teva-stock-rating-reaffirmed-by-ubs-ag.html.

Several large investors have recently modified their holdings of the business. Capital Research Global Investors boosted its stake in shares of Teva Pharmaceutical Industries Limited by 13.8% during the 2nd quarter. Capital Research Global Investors now owns 76,325,059 shares of the company’s stock valued at $2,535,518,000 after buying an additional 9,260,426 shares during the period. Franklin Resources Inc. boosted its stake in shares of Teva Pharmaceutical Industries Limited by 11.1% during the 2nd quarter. Franklin Resources Inc. now owns 66,796,897 shares of the company’s stock valued at $2,218,958,000 after buying an additional 6,685,844 shares during the period. FMR LLC boosted its stake in shares of Teva Pharmaceutical Industries Limited by 16.7% during the 2nd quarter. FMR LLC now owns 42,844,979 shares of the company’s stock valued at $1,423,310,000 after buying an additional 6,115,853 shares during the period. Northern Cross LLC boosted its stake in shares of Teva Pharmaceutical Industries Limited by 14.0% during the 2nd quarter. Northern Cross LLC now owns 17,795,579 shares of the company’s stock valued at $591,169,000 after buying an additional 2,184,172 shares during the period. Finally, Nordea Investment Management AB boosted its stake in shares of Teva Pharmaceutical Industries Limited by 2.5% during the 2nd quarter. Nordea Investment Management AB now owns 12,884,810 shares of the company’s stock valued at $428,033,000 after buying an additional 311,894 shares during the period. 56.87% of the stock is owned by institutional investors.

Teva Pharmaceutical Industries Limited Company Profile

Teva Pharmaceutical Industries Limited is a pharmaceutical company. The Company is engaged in developing, producing and marketing generic medicines and a portfolio of specialty medicines. The Company operates through two segments: Generic medicines and Specialty medicines. The Company develops, manufactures and sells generic medicines in a range of dosage forms, including tablets, capsules, injectables, inhalants, liquids, ointments and creams.

Analyst Recommendations for Teva Pharmaceutical Industries Limited (NYSE:TEVA)

Receive News & Ratings for Teva Pharmaceutical Industries Limited Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Teva Pharmaceutical Industries Limited and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply